Notícias e Atividades da Veloxis Pharmaceuticals

A Veloxis Pharmaceuticals pertence à Asahi Kasei.

Asahi Kasei é uma das ...

• Forbes Global 2000 (#1139);
• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Asahi Kasei é uma empresa listada sob o símbolo 3407 (JP).

Asahi Kasei tem presença direta em 9 países.

Asahi Kasei possui 20 subsidiárias incluindo Asahi Kasei Homes, Asahi Kasei Medical e Asahi Kasei Microdevices.

Eles estão dentro:

• Equipamentos Médicos33%
• Produtos Químicos14%
• Outro52%

Fusão, aquisição e financiamento envolvendo Asahi Kasei.

• Asahi Kasei has announced the acquisition of AiCuris  (publicado em 3 de março de 2026).

Veja o organograma con seus 9 executivos principais

Biografias mais buscadas da Veloxis Pharmaceuticals

• Stacy Wheeler, Chief Executive Officer
• Eric Hedge, Vice President, Sales
• Tracy Sapp, Vice President, Quality

Criar um alerta
para seguir os movimentos de executivos da Veloxis Pharmaceuticals.

Asahi Kasei possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).

Popular M&A news in Farmacêutica

• Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).
• Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).
• Apotex preencheu seu dossiê de IPO. Seu símbolo de ação será TSX. (publicado em 2 de junho de 2026).

Outros contatos sugeridos na indústria do Farmacêutica

• Joaquin Duato - Chief Executive Officer and Chairman of the Board da Johnson & Johnson
• Richard Saynor - Chief Executive Officer da Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board da Abbott

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Veloxis Pharmaceuticals

• Veloxis Pharmaceuticals, Inc. | Pegrizeprument Granted Orphan Drug Designation for Prevention of Organ Rejection in Heart Transplant Patients
• Veloxis Pharmaceuticals, Inc. | Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy
• Veloxis Pharmaceuticals, Inc. | Pegrizeprument Granted Orphan Drug Designation for Prevention of Organ Rejection in Patients Receiving a Liver Transplant
• Veloxis Pharmaceuticals, Inc. | Veloxis Pharmaceuticals to Present at 2025 World Transplant Congress
• Veloxis Pharmaceuticals, Inc. | Veloxis Pharmaceuticals Receives Approval from USAN for “Pegrizeprument” as Nonproprietary Name for VEL-101
• News | Veloxis Pharmaceuticals Selected to Present at the 2024 American Transplant Congress in Philadelphia
• News | Veloxis Pharmaceuticals Chief Scientific Officer to Receive National Kidney Foundation’s Market Innovation Award
• Transplant Therapeutics Consortium Receives Acceptance of Letter-of-Intent for iBox Scoring System as a Reasonably Likely Surrogate Endpoint from the Biomarker Qualification Program | Veloxis Pharmaceuticals
• Veloxis Pharmaceuticals: Asahi Kasei Pharma Denmark offentliggør det foreløbige resultat af samt afslutningen på dets offentlige købstilbud på aktier og warrants i Veloxis Pharmaceuticals | Veloxis Pharmaceuticals
• Extraordinary General Meeting of Veloxis Pharmaceuticals A/S, 17 February 2020 | Veloxis Pharmaceuticals
• View more press releases Close

Redes sociais sobre Veloxis Pharmaceuticals

• Veloxis Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Veloxis Pharmaceuticals na LinkedIn, X (Twitter) e YouTube